Needham and Company

Riverbed Technology (NASDAQ:RVBD) in Multi-Growth Pattern for WAN

Riverbed Technology (NASDAQ:RVBD) is in a multi-year growth pattern for WAN acceleration, according to Needham, which remains positive on the company. Needham says, “…We have conviction that RVBD is in a multi-year growth pattern for WAN acceleration, as the business driver of datacenter consolidation is still very strong (though years old as a driver). Complementing the “old driver” is

Continue Reading »

Bottomline Technologies (NASDAQ:EPAY) Shares Soar on Strongest Orders in History of Company

Shares of Bottomline Technologies (NASDAQ:EPAY) were up over 12 percent on the day, as they came of their best quarter for orders in the history of the company. Needham says, “Bottomline posted by far the strongest orders quarter in the firm’s history, which is indicative of the strategic value that Bottomline provides its financial institution customers. Additionally, Q2’s robust orders

Continue Reading »

Immunogen’s (NASDAQ:IMGN) Expectations Too High, as is Valuation

Immunogen’s (NASDAQ:IMGN) valuation is too high, according to Needham, which is the result of expectations concerning late-stage T-DM1. Needham says, “We believe the current valuation is built on high expectations for the late-stage T-DM1 along with the brand-name Roche (OTC:RHHBY) (N/R) partnership, but the value creation for ImmunoGen is modest, due to the mid-single digit royalty. Despite the

Continue Reading »

Needham Positive on Biolase (NASDAQ:BLTI) over Long Term

Citing the recent restructuring of the HSIC deal, and several other postive developments, Needham says they’re postive on Biolase Technology (NASDAQ:BLTI) over the long term. Needham said, “In addition to the restructuring of the HSIC deal, the company has had a number of recent positive developments that give us reason for optimism about its long term prospects: BLTI has already received a

Continue Reading »